Leptomeningeal metastatic l858r egfr -mutant lung cancer: prompt response to osimertinib in the absence of t790m-mutation and effective subsequent pulsed erlotinib

HIGHLIGHTS

• who: EGFR-TKIs and collaborators from the Laboratory Medicine and Pathology, Hamad Medical have published the research: Leptomeningeal Metastatic L858R EGFR -mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib, in the Journal: (JOURNAL) of 14/06/2022
• what: Osimertinib can result in clinical and radiological response, with extended survival when used for EGFR-mutant T790Mnegative lung adenocarcinoma progressed to LMC.

SUMMARY

Dovepress Tumors that develop resistance to EGFR-TKIs, mostly due to EGFR-T790M mutation, represent a challenge for durable response . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.